Plague vaccine study for healthy adults
Part of Infections clinical trials.
This study tests an experimental vaccine to protect against plague. It's for healthy adults 18 to 55 who haven't had plague or the vaccine before. The goal is to see if the vaccine is safe and creates a strong immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 55 years old
- You are generally healthy or have a stable medical condition (no major changes in medications or hospital stays in the last 3 months)
- You have never had plague disease or received a plague vaccine before
- You do not have HIV, hepatitis B, hepatitis C, an autoimmune disease, or active tuberculosis
- You have not used certain immune-suppressing drugs (like high-dose steroids) for more than 14 days in the last 90 days
- Your BMI is under 30
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a new vaccine called V118E is safe and well-tolerated in healthy people. It is for adults who are in good health and have not recently had a pneumococcal infection.
This study tests a new RSV vaccine called YKYY025 in healthy adults. The main goal is to see if it is safe and to measure how the immune system responds.
This study tests if two new vaccines (one for shingles, one for RSV) affect heart artery plaque in people 50 and older who have some risk factors for heart disease. It aims to see if the vaccines are safe and if they slow plaque buildup.
This trial tests whether a pneumococcal vaccine can help protect against a specific type of pneumonia bacteria. Researchers want to see if the vaccine can create antibodies that work against multiple strains.
This trial tests a new monkeypox vaccine to see if it's safe and works. It's for healthy adults who haven't had monkeypox or smallpox before.
This study tests an experimental RSV vaccine (IN006) in healthy adults to check its safety and how well it triggers an immune response. It may help protect against respiratory syncytial virus (RSV), which can cause serious lung infections.
Hear when a new Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.